|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Satsuma Pharmaceuticals, Inc. (STSA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
31,530,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapeutic product for the acute treatment of migraine. Co.'s product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. Co.'s development plan for STS101 included a completed Phase 1 trial; a Phase 3 efficacy trial (the SUMMIT trial), which is ongoing; and continuation of the open-label, Phase 3 long-term safety trial of STS101 (the ASCEND trial).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
52,530,894 |
59,120,894 |
| Total Buy Value |
$0 |
$0 |
$47,803,114 |
$52,304,126 |
| Total People Bought |
0 |
0 |
2 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
3,250,000 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,294,500 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-05-05 |
4 |
AS |
$20.00 |
$20,000 |
D/D |
(1,000) |
20,212 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-05-05 |
4 |
OE |
$4.56 |
$4,560 |
D/D |
1,000 |
21,212 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-04-14 |
4/A |
AS |
$20.00 |
$16,000 |
D/D |
(800) |
20,212 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-04-14 |
4/A |
OE |
$4.56 |
$3,648 |
D/D |
800 |
21,012 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-04-14 |
4 |
AS |
$20.00 |
$16,000 |
D/D |
(800) |
20,012 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-04-14 |
4 |
OE |
$4.56 |
$3,648 |
D/D |
800 |
20,812 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-04-01 |
4/A |
AS |
$20.25 |
$4,049 |
D/D |
(200) |
20,212 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-04-01 |
4 |
AS |
$20.25 |
$4,049 |
D/D |
(200) |
20,012 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-04-01 |
4 |
OE |
$4.56 |
$912 |
D/D |
200 |
20,412 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-03-11 |
4 |
AS |
$27.42 |
$27,422 |
D/D |
(1,000) |
20,212 |
|
- |
|
| Albrecht Detlef |
Chief Medical Officer |
• – – |
2020-03-11 |
4 |
OE |
$4.56 |
$4,560 |
D/D |
1,000 |
21,212 |
|
- |
|
| Oneil Thomas P. |
Chief Financial Officer |
• – – |
2020-03-11 |
4 |
AS |
$27.68 |
$27,678 |
D/D |
(1,000) |
0 |
|
- |
|
| Oneil Thomas P. |
Chief Financial Officer |
• – – |
2020-03-11 |
4 |
OE |
$4.56 |
$4,560 |
D/D |
1,000 |
1,000 |
|
- |
|
| Coulter James G |
10% Owner |
– – • |
2019-09-17 |
4 |
B |
$15.00 |
$1,500,000 |
I/I |
100,000 |
1,885,939 |
1.5 |
- |
|
| Coulter James G |
10% Owner |
– – • |
2019-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
1,785,939 |
1,785,939 |
|
- |
|
| Hadley Harbor Master Investors (cayman) Ii L.p. |
10% Owner |
– – • |
2019-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
1,105,154 |
1,105,154 |
|
- |
|
| Kolchinsky Peter |
10% Owner |
– – • |
2019-09-17 |
4 |
B |
$15.00 |
$19,999,995 |
I/I |
1,333,333 |
4,681,858 |
1.5 |
- |
|
| Kolchinsky Peter |
10% Owner |
– – • |
2019-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,348,525 |
3,348,525 |
|
- |
|
| Shah Rajeev M. |
Director |
– • • |
2019-09-17 |
4 |
B |
$15.00 |
$19,999,995 |
I/I |
1,333,333 |
4,681,858 |
2.25 |
- |
|
| Shah Rajeev M. |
Director |
– • • |
2019-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,348,525 |
3,348,525 |
|
- |
|
| Takanashi Ken |
Director |
– • – |
2019-09-17 |
4 |
B |
$15.00 |
$3,499,995 |
I/I |
233,333 |
1,561,719 |
2.1 |
- |
|
| Takanashi Ken |
Director |
– • – |
2019-09-17 |
4 |
A |
$0.00 |
$0 |
I/I |
340,851 |
1,328,386 |
|
- |
|
| Kollins John A |
President and CEOOfficer |
• • – |
2019-09-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
305,911 |
|
- |
|
| Albrecht Detlef |
Chief Medical OfficerOfficer |
• – – |
2019-09-12 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,212 |
|
- |
|
74 Records found
|
|
Page 3 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
